US rejects experimental painkiller
New York, April 23, 2010
US government advisers have urged regulators to reject an experimental painkiller from King Pharmaceuticals and Acura Pharmaceuticals.
The Acurox pill was designed to discourage abuse by adding the vitamin niacin to the painkiller oxycodone. The companies said people who take multiple pills would get high doses of niacin that could cause uncomfortable flushing.
Members of a Food and Drug Administration (FDA) advisory panel praised the drugmakers for trying to reduce improper use but said they had not shown niacin would be a strong deterrent.
The FDA usually follows panel recommendations when deciding whether to approve new medicines.
King shares closed down 2.8 per cent at $11.10 on the New York Stock Exchange. Acura shares were halted on the Nasdaq while the panel met.-Reuters
More Health & Environment Stories
- Dust haze in Bahrain ‘set to continue’
- Bahrain’s new plan to tackle power, water
- Masdar launches wind farm in Seychelles
- IHG marks environment day
- SARS-like virus kills four more in Saudi
- Cinfa eyes growth into regional markets
- Nissan tops 2013 green brand list
- Bahrain to launch organ donation database
- EmiratesGBC wins key role in UAE tourism
- Waha Capital buys stake in healthcare firm